Chen · Frontiers in public health 2026 · structured narrative review · n=?

Gut microbiota-intestinal barrier crosstalk: mechanistic advances, disease relevance, and public health implications.

Cited 1 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Structured narrative review synthesizing mechanistic, preclinical, and clinical studies without meta-analysis.

PubMed 42158204 · doi:10.3389/fpubh.2026.1777910 · record verified 2026-08-30

What was done

The authors performed a structured literature review of studies published between 2019 and 2025 across PubMed, Scopus, and Web of Science. The review synthesized mechanistic, preclinical, and clinical evidence regarding bidirectional interactions between the gut microbiota and the intestinal barrier, focusing on microbial metabolites, tight junction integrity, mucosal immune regulation, disease associations, and microbiota-targeted interventions (such as prebiotics, probiotics, dietary changes, and fecal microbiota transplantation).

What was found

The abstract reports no numerical data, pooled statistics, or effect estimates. It qualitatively reports that microbiota-derived metabolites (short-chain fatty acids, indole derivatives, and bile acids) regulate intestinal barrier integrity by modulating tight junction expression, mucin production, and mucosal immunity. In turn, barrier disruption promotes microbial translocation, endotoxemia, and chronic inflammation, contributing to inflammatory bowel disease, type 2 diabetes, metabolic-associated fatty liver disease, and neurodegenerative disorders. The review notes that microbiota-targeted interventions show potential for barrier restoration but display inconsistent clinical outcomes.

Why it matters

This paper aggregates mechanistic and clinical evidence to frame the gut microbiota-intestinal barrier axis as a unified mechanism underlying diverse chronic non-communicable diseases and explores its potential for public health prevention strategies.

Limits

The review does not report a quantitative meta-analysis, risk-of-bias grading, or the total number of reviewed studies (n = ?). The evidence base is limited by substantial heterogeneity in study designs, lack of intervention standardization, inconsistent clinical results, and incomplete causal validation in humans.

Cited by